Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 4, 2013, Pages 944-948

  Valdenaire, Anja ^a   Pothier, Julien ^a   Renneberg, Dorte ^a   Riederer, Markus A ^a   Peter, Oliver ^a   Leroy, Xavier ^a   Gnerre, Carmela ^a   Fretz, Heinz ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Asthma; CRTh2; DP2; Prostaglandin; Rhinitis

Indexed keywords

2 CYANO 3(1H INDOL 3 YL)ACRYLAMIDE; 2,3,4,5 TETRAHYDRO 1H PYRIDO [4,3 BETA] INDOLE; ACRYLAMIDE DERIVATIVE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR CRTH2; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG HALF LIFE; IC 50; RING CLOSING METATHESIS; STRUCTURE ACTIVITY RELATION;

ACRYLAMIDES; ANIMALS; HUMANS; INDOLES; MODELS, MOLECULAR; RATS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84872924984     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.12.050     Document Type: Article

References (23)

1. J.J. Murray, A.B. Tonnel, and A.R.N. Brash Engl. J. Med. 315 1986 800
2. F.G. Gervais, R.P. Cruz, A. Chateauneuf, S. Gale, N. Sawyer, F. Nantel, K.M. Metters, and G.P. O'Neill J. Allergy Clin. Immunol. 108 2001 982
3. H. Hirai, K. Tanaka, O. Yoshie, K. Ogawa, K. Kenmotsu, Y. Takamori, M. Ichimasa, K. Sugamura, M. Nakamura, S. Takano, and K. Nagata J. Exp. Med. 193 2001 255
4. R. Pettipher Br. J. Pharmacol. 153 2008 S191
5. E. Kostenis, and T. Ulven Trends Mol. Med. 12 2006 148
6. R. Pettipher, T.T. Hansel, and R. Armer Nat. Rev. Drug Disc. 6 2007 313
7. J.J. Chen, and A.L. Budelsky Prog. Med. Chem. 50 2011 49
8. L.E. Burgess Annu. Rep. Med. Chem. 46 2011 119
9. R. Schuligoi, E. Sturm, P. Luschnig, V. Konya, S. Philipose, M. Sedj, M. Waldhoer, B.A. Peskar, and A. Heinemann Pharmacology 85 2010 372
10. R. Pettipher, and T.T. Hansel Prog. Respir. Res. 39 2010 193 Karger: Basel
11. J. Pothier, M.A. Riederer, O. Peter, X. Leroy, A. Valdenaire, C. Gnerre, and H. Fretz Bioorg. Med. Chem. Lett. 22 2012 4660
12. Such structural alerts are not per se prohibitive for further drug development, as exemplified with approved Entacapone and Teriflunomide, both drugs comprising features related to this hit series.
13. T. Hirata, and S. Narumiya Chem. Rev. 111 2011 6209
14. E. Knoevenagel Chem. Ber. 27 1894 2345
15. M. Schwarz J. Chem. Soc., Chem. Commun. 1969 212
16. J. Zabicky J. Chem. Soc., Chem. Commun. 1961 683
17. V.N. Sonar, S. Parkin, and P.A. Crooks Acta Cryst. E62 2006 o1077
18. Preparative reverse phase HPLC on a Atlantis Prep T3, 10 μm, 30 × 75 mm column; eluent A: acetonitrile, eluent B: water containing 0.5% formic acid; gradient: 10-90% A in 4 min.; flow rate: 75 ml/min.
19. D.K. Barma, A. Kundu, H. Zhank, Ch. Mioskowski, and J.R. Falck J. Am. Chem. Soc. 125 2003 3218
20. V.E. Stubbs, P. Schratl, A. Hartnell, T.J. Williams, B.A. Peskar, A. Heinemann, and I. Sabroe J. Biol. Chem. 277 2002 26012
21. I. Sabroe, A. Hartnell, L.A. Jopling, S. Bel, P.D. Ponath, J.E. Pease, P.D. Collins, and T.J. Williams J. Immunol 162 1999 2946
22. E.B. Asafu-Adjaye, P.J. Faustino, M.A. Tawakull, L.W. Anderson, L.X. Yu, H. Kwon, and D.A. Volpe J. Pharm. Biomed. Anal. 43 2007 1854
23. Fecher, A.; Fretz, H.; Riederer M. WO2006070325 (Actelion Pharmaceuticals Ltd, Switz.), PCT Int. Appl. (2006).